2. Search Result
Search Result
Results for "

chemotherapy-induced

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

2

Peptides

1

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14407A
    Fosaprepitant dimeglumine
    2 Publications Verification

    MK-0517; L785298

    		 Neurokinin Receptor Neurological Disease Endocrinology Cancer
    Fosaprepitant dimeglumine (MK-0517) is a proagent of Aprepitant (HY-10052). Fosaprepitant dimeglumine is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV) .
    Fosaprepitant dimeglumine
  • HY-P3761
    Ac-Tyr-Val-Lys-Asp-aldehyde

    		Caspase Others
    Ac-Tyr-Val-Lys-Asp-aldehyde is a caspase-1 inhibitor, can be used for disease research including anemia-associated to chronic diseases, chemotherapy-induced anemia and Diamond-Blackfan anemia .
    Ac-Tyr-Val-Lys-Asp-aldehyde
  • HY-B0993
    Mangafodipir trisodium

    MnDPDP

    		 Apoptosis Neurological Disease Cancer
    Mangafodipir trisodium (MnDPDP), hepatocellular-specific contrast agent, is an efficacious inhibitor of CIPN (chemotherapy-induced peripheral neuropath) and other conditions caused by cellular oxidative stress. Mangafodipir trisodium shows no negative interference with the tumoricidal activity of chemotherapy .
    Mangafodipir trisodium
  • HY-123239
    KLS-13019

    		GPR55 Neurological Disease
    KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats .
    KLS-13019
  • HY-B0993A
    Mangafodipir

    		Biochemical Assay Reagents Cancer
    Mangafodipir, hepatocellular-specific contrast agent, is an efficacious inhibitor of CIPN (chemotherapy-induced peripheral neuropath) and other conditions caused by cellular oxidative stress. Mangafodipir shows no negative interference with the tumoricidal activity of chemotherapy .
    Mangafodipir
  • HY-14407
    Fosaprepitant

    L-758298

    		 Neurokinin Receptor Neurological Disease Endocrinology Cancer
    Fosaprepitant (L-785298) is a proagent of Aprepitant (HY-10052). Fosaprepitant is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV) .
    Fosaprepitant
  • HY-14407AR
    Fosaprepitant dimeglumine (Standard)

    		Neurokinin Receptor Neurological Disease Endocrinology Cancer
    Fosaprepitant (dimeglumine) (Standard) is the analytical standard of Fosaprepitant (dimeglumine). This product is intended for research and analytical applications. Fosaprepitant dimeglumine (MK-0517) is a proagent of Aprepitant (HY-10052). Fosaprepitant dimeglumine is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV) .
    Fosaprepitant dimeglumine (Standard)
  • HY-A0018
    Palonosetron

    		5-HT Receptor Cardiovascular Disease
    Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).
    Palonosetron
  • HY-155089
    IACS-52825

    		MAP3K Neurological Disease
    IACS-52825 is a potent and selective DLK inhibitor with Kd of 1.3 nM, useful for the study of chemotherapy-induced peripheral neuropathy .
    IACS-52825
  • HY-A0021R
    Palonosetron hydrochloride (Standard)

    		5-HT Receptor Cardiovascular Disease Cancer
    Palonosetron (hydrochloride) (Standard) is the analytical standard of Palonosetron (hydrochloride). This product is intended for research and analytical applications. Palonosetron hydrochloride is a 5-HT3 antagonist that inhibits chemotherapy-induced nausea and vomiting (CINV).
    Palonosetron hydrochloride (Standard)
  • HY-B0068
    Azasetron hydrochloride
    2 Publications Verification

    Y-25130 hydrochloride

    		 5-HT Receptor Neurological Disease
    Azasetron (Y-25130) hydrochloride, a benzamide derivative, is a potent and selective 5-HT3 receptor antagonist. Azasetron is used in the study for Chemotherapy-induced nausea and vomiting (CINV) .
    Azasetron hydrochloride
  • HY-A0021S
    Palonosetron-d3 hydrochloride

    		5-HT Receptor Cardiovascular Disease
    Palonosetron-d3 (hydrochloride) is the deuterium labeled Palonosetron hydrochloride. Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV)[1][2].
    Palonosetron-d3 hydrochloride
  • HY-147306A
    (S)-ZLc002

    		NO Synthase Neurological Disease
    (S)-ZLc002 is a S-enantiomer of ZLc-002. ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain .
    (S)-ZLc002
  • HY-14405B
    (R)-Casopitant

    (R)-GW679769

    		 Neurokinin Receptor Cancer
    (R)-Casopitant ((R)-GW679769) is the isomer of Casopitant (HY-14405). Casopitant is a NK(1)-receptor antagonist. Casopitant can be used for the research of chemotherapy-induced nausea and vomiting .
    (R)-Casopitant
  • HY-B0750S1
    Dolasetron-d5

    MDL-73147-d5

    		 5-HT Receptor Isotope-Labeled Compounds Cancer
    Dolasetron-d5 is deuterated labeled Dolasetron (HY-B0750). Dolasetron (MDL-73147) is a 5-HT3 receptor antagonist with potential for treatment of chemotherapy-induced nausea and vomiting.
    Dolasetron-d5
  • HY-147306
    ZLc-002

    		Others Neurological Disease
    ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation .
    ZLc-002
  • HY-111791
    ACY-1083
    1 Publications Verification

    		 HDAC Cancer
    ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor with an IC50 of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy .
    ACY-1083
  • HY-124996
    (Rac)-ZLc-002

    		NO Synthase Neurological Disease Inflammation/Immunology Cancer
    (Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability .
    (Rac)-ZLc-002
  • HY-14407AS
    Fosaprepitant-d4 dimeglumine

    MK-0517-d4; L785298-d4

    		 Isotope-Labeled Compounds Neurokinin Receptor Neurological Disease Endocrinology Cancer
    Fosaprepitant-d4 (dimeglumine) is deuterium labeled Fosaprepitant (dimeglumine). Fosaprepitant dimeglumine (MK-0517) is a proagent of Aprepitant (HY-10052). Fosaprepitant dimeglumine is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV)[1].
    Fosaprepitant-d4 dimeglumine
  • HY-A0021
    Palonosetron hydrochloride
    1 Publications Verification

    		 5-HT Receptor Flavivirus Cardiovascular Disease Cancer
    Palonosetron hydrochloride is a 5-HT3 antagonist primarily used to prevent acute, delayed, and overall chemotherapy-induced nausea and vomiting. In addition, Palonosetron hydrochloride exhibits moderate anti-flavivirus activity and potent anti-Zika virus activity in mammalian cells. Palonosetron hydrochloride also possesses antidepressant activity .
    Palonosetron hydrochloride
  • HY-W097625
    6-Methoxyflavone

    		Others Neurological Disease Inflammation/Immunology
    6-Methoxyflavone is a methoxyflavone that can be isolated from Pimelea simplex F. Muell. and P. decora Domin.. 6-Methoxyflavone exhibits anti-inflammatory effects and neuropathic pain relieving properties in chemotherapy-induced peripheral neuropathy (CIPN). 6-Methoxyflavone can be used in the research of nephritis .
    6-Methoxyflavone
  • HY-B0415
    Fluocinolone (Acetonide)

    		Glucocorticoid Receptor Wnt Inflammation/Immunology Endocrinology
    Fluocinolone is a glucocorticoid glucocorticoid receptor agonist. Fluocinolone is effective in preventing both lipid accumulation and inflammation. Fluocinolone can promote the proliferation of DPCs and has the potential role in repairing injured pulp tissues. Fluocinolone can be used to study the prevention of chemotherapy-induced peripheral neuropathy caused by Paclitaxel (HY-B0015) .
    Fluocinolone (Acetonide)
  • HY-103347
    M50054

    		Apoptosis Inflammation/Immunology
    M50054 is a potent inhibitor of apoptosis. M50054 inhibits Etoposide-induced caspase-3 activation of U937 cells with an IC50 of 79 μg/mL. M50054 does not directly inhibit the enzymatic activity of caspase-3. M50054 can be used for the research anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia .
    M50054
  • HY-14405A
    Casopitant mesylate

    GW679769B

    		 Neurokinin Receptor Cytochrome P450 Neurological Disease Cancer
    Casopitant mesylate (GW679769B) is a potent, selective, brain permeable and orally active neurokinin 1 (NK1) receptor antagonist. Casopitant mesylate is a second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P. Casopitant mesylate is also a substrate and a weak-to-moderate inhibitor of CYP3A4. Casopitant mesylate can be used for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) .
    Casopitant mesylate
  • HY-148948
    Nampt activator-3

    		NAMPT Neurological Disease
    NAMPT activator-3, a NAT derivative, is a NAMPT activator with an EC50 of 2.6 μM and a KD of 132 nM. NAMPT activator-3 effectively protects cultured cells from FK866 (HY-50876)-mediated toxicity. NAMPT activator-3 exhibits strong neuroprotective efficacy in a chemotherapy-induced peripheral neuropathy (CIPN) mouse model without any overt toxicity .
    Nampt activator-3
  • HY-106982
    Ezlopitant

    CJ-11,974

    		 Neurokinin Receptor Neurological Disease Metabolic Disease
    Ezlopitant (CJ-11,974) is a selective, non-peptidic neurokinin-1 (NK-1)-receptor antagonist. Ezlopitant inhibits both acute and delayed emetic reactions induced by Cisplatin (HY-17394) in ferrets via acting on NK1 receptors in the central nervous system. Ezlopitant has the potential for pain, chemotherapy-induced emesis and irritable bowel syndrome research .
    Ezlopitant
  • HY-B0019
    Azasetron

    (Rac)-SENS-401 free base

    		 Others Neurological Disease
    Azasetron ((Rac)-SENS-401 free base) is an antiemetic drug with 5-HT3 receptor antagonist activity. Azasetron is often used as a preventive measure for postoperative nausea and vomiting or chemotherapy-induced nausea and vomiting. Azasetron does not impair neutrophil chemotaxis or phagocytosis and does not scavenge O(-)(2) or H(2)O(2) generated by cell-free systems .
    Azasetron
  • HY-B0415R
    Fluocinolone (Acetonide) (Standard)

    		Glucocorticoid Receptor Wnt Inflammation/Immunology Endocrinology
    Fluocinolone (Acetonide) (Standard) is the analytical standard of Fluocinolone (Acetonide). This product is intended for research and analytical applications. Fluocinolone is a glucocorticoid glucocorticoid receptor agonist. Fluocinolone is effective in preventing both lipid accumulation and inflammation. Fluocinolone can promote the proliferation of DPCs and has the potential role in repairing injured pulp tissues. Fluocinolone can be used to study the prevention of chemotherapy-induced peripheral neuropathy caused by Paclitaxel (HY-B0015) .
    Fluocinolone (Acetonide) (Standard)
  • HY-14909
    Bardoxolone
    Maximum Cited Publications
    15 Publications Verification

    CDDO; RTA 401

    		 Keap1-Nrf2 Necroptosis Metabolic Disease Cancer
    Bardoxolone (RTA 401; CDDO) is a novel nuclear regulatory factor (NRf-2) activator. Bardoxolone is a potent necroptosis inhibitor that inhibits Z-VAD-FMK-induced necroptosis. Bardoxolone methyl enhances the antioxidant system, modulates inflammatory cytokines and inhibits apoptosis in rat kidney, demonstrating inhibition on APAP-induced acute kidney injury (AKI) and analgesic effect. Additionally, Bardoxolone methyl decreases Paclitaxel (PAC) (HY-B0015)-induced mitochondrial damage in neuronal cells. Bardoxolone methyl is promising for the research of chemotherapy-induced neuropathic pain and chronic kidney disease .
    Bardoxolone
  • HY-161918
    SARM1-IN-3

    		Others Neurological Disease
    SARM1-IN-3 (Example 30) is a SARM1 inhibitor. SARM1-IN-3 can be used in the study of chemotherapy induced peripheral neuropathy (CIPN) .
    SARM1-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: